HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hedrick, C. C. Articles by Lusis, A. J. Search for Related Content PubMed PubMed Citation Articles by Hedrick, C. C. Articles by Lusis, A. J. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 42, 563-570, April 2001
Copyright © 2001 by Lipid Research, Inc.

Original Article

In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions

Correspondence to: Catherine C. Hedrick, at the Department of Endocrinology and Metabolism, MR-4, Room 5116, Lane Road, P.O. Box 801405, University of Virginia, Charlottesville, VA 22908., cch6n{at}virginia.edu (E-mail)

Studies with mice have revealed that increased expression of apolipoprotein A-II (apoA-II) results in elevations in high density lipoprotein (HDL), the formation of larger HDL, and the development of early atherosclerosis. We now show that the increased size of HDL results in part from an inhibition of the ability of hepatic lipase (HL) to hydrolyze phospholipids and triglycerides in the HDL and that the ratio of apoA-I to apoA-II determines HDL functional and antiatherogenic properties. HDL from apoA-II transgenic mice was relatively resistant to the action of HL in vitro. To test whether HL and apoA-II influence HDL size independently, combined apoA-II transgenic/HL knockout (HLko) mice were examined. These mice had HDL similar in size to apoA-II transgenic mice and HLko mice, suggesting that they do not increase HDL side by independent mechanisms. Overexpression of apoA-I from a transgene reversed many of the effects of apoA-II overexpression, including the ability of HDL to serve as a substrate for HL. Combined apoA-I/apoA-II transgenic mice exhibited significantly less atherosclerotic lesion formation than did apoA-II transgenic mice. These results were paralleled by the effects of the transgenes on the ability of HDL to protect against the proinflammatory effects of oxidized low density lipoprotein (LDL). Whereas nontransgenic HDL protected against oxidized LDL induction of adhesion molecules in endothelial cells, HDL from apoA-II transgenic mice was proinflammatory. HDL from combined apoA-I/apoA-II transgenic mice was equally as protective as HDL from nontransgenic mice.

Our data suggest that as the ratio of apoA-II to apoA-I is increased, the HDL become larger because of inhibition of HL, and lose their antiatherogenic properties. — Hedrick, C. C., L. W. Castellani, H. Wong, and A. J. Lusis. In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions. J. Lipid Res. 2001. 42: 563;–570.

Supplementary key words: atherosclerosis, lipoprotein, paraoxonase, transgenic mice

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. A. G. D. Silva, L. A. Schneeweis, S. C. Krishnan, X. Zhang, P. H. Axelsen, and W. S. Davidson The Structure of Apolipoprotein A-II in Discoidal High Density Lipoproteins J. Biol. Chem., March 30, 2007; 282(13): 9713 - 9721. [Abstract] [Full Text] [PDF]

				A. C. L. Cervino, A. Darvasi, M. Fallahi, C. C. Mader, and N. F. Tsinoremas An Integrated in Silico Gene Mapping Strategy in Inbred Mice Genetics, January 1, 2007; 175(1): 321 - 333. [Abstract] [Full Text] [PDF]

				S. Jayaraman, D. L. Gantz, and O. Gursky Kinetic Stabilization and Fusion of Apolipoprotein A-2:DMPC Disks: Comparison with apoA-1 and apoC-1 Biophys. J., April 1, 2005; 88(4): 2907 - 2918. [Abstract] [Full Text] [PDF]

				W. Shi, H. Pei, J. J. Fischer, J. C. James, J. F. Angle, A. H. Matsumoto, G. A. Helm, and I. J. Sarembock Neointimal formation in two apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility J. Lipid Res., November 1, 2004; 45(11): 2008 - 2014. [Abstract] [Full Text] [PDF]

				K. B. Reilly, S. Srinivasan, M. E. Hatley, M. K. Patricia, J. Lannigan, D. T. Bolick, G. Vandenhoff, H. Pei, R. Natarajan, J. L. Nadler, et al. 12/15-Lipoxygenase Activity Mediates Inflammatory Monocyte/Endothelial Interactions and Atherosclerosis in Vivo J. Biol. Chem., March 5, 2004; 279(10): 9440 - 9450. [Abstract] [Full Text] [PDF]

				K. Conde-Knape, A. Bensadoun, J. H. Sobel, J. S. Cohn, and N. S. Shachter Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase J. Lipid Res., December 1, 2002; 43(12): 2136 - 2145. [Abstract] [Full Text] [PDF]

				Z. Su, S. Zhang, D. W. Nebert, L. Zhang, D. Huang, Y. Hou, L. Liao, and C. Xiao A novel allele in the promoter of the hepatic lipase is associated with increased concentration of HDL-C and decreased promoter activity J. Lipid Res., October 1, 2002; 43(10): 1595 - 1601. [Abstract] [Full Text] [PDF]

				J. Julve, J. C. Escola-Gil, V. Ribas, F. Gonzalez-Sastre, J. Ordonez-Llanos, J. L. Sanchez-Quesada, and F. Blanco-Vaca Mechanisms of HDL deficiency in mice overexpressing human apoA-II J. Lipid Res., October 1, 2002; 43(10): 1734 - 1742. [Abstract] [Full Text] [PDF]

				H. Jansen, A. J. M. Verhoeven, and E. J. G. Sijbrands Hepatic lipase: a pro- or anti-atherogenic protein? J. Lipid Res., September 1, 2002; 43(9): 1352 - 1362. [Abstract] [Full Text] [PDF]

				F. Blanco-Vaca, J. C. Escola-Gil, J. M. Martin-Campos, and J. Julve Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein J. Lipid Res., November 1, 2001; 42(11): 1727 - 1739. [Abstract] [Full Text] [PDF]